Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop
Corbus Pharmaceuticals experienced a significant stock decline following the release of Phase 1/2b data for its CRB-701 treatment. The data revealed an overall response rate of 43% in second-line OPSCC and 34.4% in second-line cervical cancer, which did not meet market expectations. Analysts are advising caution regarding the stock's future performance amidst competition and market outlook.
- ▪Corbus Pharmaceuticals Holdings, Inc. stock fell sharply after disappointing Phase 1/2b data for CRB-701.
- ▪The treatment showed a 43% overall response rate in second-line OPSCC and 34.4% in second-line cervical cancer.
- ▪Market analysts suggest investors should exercise caution in light of the recent selloff.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909223-corbus-pharmaceuticals-id-preach-caution-after-selloff-on-latest-data-drop"},"author":{"@type":"Person","name":"Edmund Ingham","url":"https://seekingalpha.com/author/edmund-ingham"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
